New insights into the mechanism of action of immune checkpoint antibodies

Oncoimmunology. 2014 Aug 3;3(8):e954869. doi: 10.4161/21624011.2014.954869. eCollection 2014.


Preclinical models have been developed and applied to predict the clinical efficacy of immune checkpoint antibodies. Now these models can be used to dissect the mechanisms by which such immunotherapeutic antibodies work and to build the rationale for combining immune checkpoint-targeting antibodies with potential synergistic activity in cancer patients.

Keywords: CTLA-4; GITR; OX40; cancer; immune checkpoint antibodies; immunotherapy.